The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Open accessAbstract
BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Zoledronic acid is also indicated for the prevention of new clinical fractures in patients (both women and men) who have recently had a low-trauma (osteoporosis-related) hip fracture [58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281
Flagged first, then by citations
Research works printed but not linked: 2
- Davidson CW, 2001, N Z Med J, 114, 329
- 2003, World Health Organ Tech Rep Ser, 921, 1
Cited by
Sorted by citations
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
“Zoledronic acid is also indicated for the prevention of new clinical fractures in patients (both women and men) who have recently had a lowtrauma (osteoporosis-related) hip fracture [58].”
BackgroundEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,993
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
Papaioannou, A., Morin, S. N., Cheung, A. M., Atkinson, S. A., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A. B., Jamal, S. A., Kaiser, S., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,768
Bliuc, D. (2009) · JAMA · doi:10.1001/jama.2009.50 · Cited by 1,695
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,442
Khan, A. A., Morrison, A. D., Hanley, D. A., Felsenberg, D., McCauley, L. K., O’Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,360
Bone regenerative medicine: classic options, novel strategies, and future directions
Oryan, A., Alidadi, S., Moshiri, A., & Maffulli, N. (2014) · Journal of Orthopaedic Surgery and Research · doi:10.1186/1749-799x-9-18 · Cited by 1,294
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Targeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,164
Excess mortality following hip fracture: a systematic epidemiological review
Abrahamsen, B., van Staa, T., Ariely, R., Olson, M., & Cooper, C. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0920-3 · Cited by 1,079
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J. E., Cooper, A., Cooper, C. C., Gittoes, N. J. L., Gregson, C. L., Harvey, N. C., Hope, S., Kanis, J. А., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 865
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. А., Burlet, N., Cooper, C. C., Delmas, P. D., Reginster, J., Borgström, F., & Rizzoli, R. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 796
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Self-citationManagement of Acute Hip Fracture
Bhandari, M., & Swiontkowski, M. F. (2017) · New England Journal of Medicine · doi:10.1056/nejmcp1611090 · Cited by 682
Adler, R. A., Fuleihan, G. E., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J.-A., Favus, M. J., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 689
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Siris, E. S., Adler, R. A., Bilezikian, J. P., Bolognese, M. A., Dawson‐Hughes, B., Favus, M. J., Harris, S. T., de Beur, S. M. J., Khosla, S., Lane, N. E., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2655-z · Cited by 673
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 602
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 547
Kannegaard, P. N., Mark, S., Eiken, P., & Abrahamsen, B. (2010) · Age and Ageing · doi:10.1093/ageing/afp221 · Cited by 534
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Self-citationCamacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M. R., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 460
Perazella, M. A., & Markowitz, G. S. (2008) · Kidney International · doi:10.1038/ki.2008.356 · Cited by 424
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R. R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 414
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Wong, S., Wiessing, K. R., Bolland, M. J., Bastin, S., & Gamble, G. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808082 · Cited by 404
The relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A. A., Dunford, J. E., Barnett, B. L., Oppermann, U. C. T., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 402
Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions
Krieg, M.-A., Barkmann, R., Gonnelli, S., Stewart, A., Bauer, D. C., Barquero, L. M. D. R., Kaufman, J. J., Lorenc, R., Miller, P. D., Olszynski, W. P., et al. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.011 · Cited by 387
Eisman, J. A., Bogoch, E. R., Dell, R., Harrington, J. T., McKinney, R. E., McLellan, A. R., Mitchell, P., Silverman, S. L., Singleton, R., Siris, E. S., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1698 · Cited by 386
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
Lenart, B. A., Neviaser, A. S., Lyman, S. L., Chang, C. C., Edobor‐Osula, F., Steele, B., van der Meulen, M. C. H., Lorich, D. G., & Lane, J. M. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0805-x · Cited by 383
Adverse Effects of Bisphosphonates
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 371
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359
Self-citationChange in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M., Eastell, R., Lui, L., Wu, L., de Papp, A. E., Grauer, A., Marín, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 357
Risk of subsequent fracture after prior fracture among older women
Balasubramanian, A., Zhang, J., Chen, L., Wenkert, D., Daigle, S. G., Grauer, A., & Curtis, J. R. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4732-1 · Cited by 347
Self-citationCardiovascular Diseases and Risk of Hip Fracture
Sennerby, U. (2009) · JAMA · doi:10.1001/jama.2009.1463 · Cited by 337
Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0852 · Cited by 335
Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., Miyauchi, A., Maddox, J., Chen, L., & Horlait, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02163 · Cited by 332
Ebeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332
Guidelines for the management of osteoporosis and fragility fractures
Nuti, R., Brandi, M. L., Checchia, G., Di Munno, O., Dominguez, L., Falaschi, P., Fiore, C. E., Iolascon, G., Maggi, S., Michieli, R., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1874-2 · Cited by 328
Bisphosphonate-associated adverse events
Papapetrou, P. D. (2009) · HORMONES · doi:10.14310/horm.2002.1226 · Cited by 317
Ayers, C. K., Kansagara, D. L., Lazur, B. H., Fu, R. F., Kwon, A., & Harrod, C. S. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 297
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
Visekruna, M., Wilson, D., & McKiernan, F. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2803 · Cited by 267
Osteonecrosis of the jaw — Who gets it, and why?
Reid, I. R. (2008) · Bone · doi:10.1016/j.bone.2008.09.012 · Cited by 265
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures
Crandall, C. J., Newberry, S. J., Diamant, A. L., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 257
Black, D. M., Reid, I. R., Cauley, J. A., Cosman, F., Leung, P., Lakatos, P., Lippuner, K., Cummings, S. R., Hue, T. F., Mukhopadhyay, A., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2442 · Cited by 260
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Åkesson, K., Alexander, I. M., Amenta, K. C., Blank, R. D., Brox, W. T., Carmody, E. E., Chapman‐Novakofski, K., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3877 · Cited by 254
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
Reid, I. R., Gamble, G. D., Mesenbrink, P. G., Lakatos, P. L., & Black, D. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0597 · Cited by 253
Self-citationTreatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
Cosman, F., Nieves, J. W., & Dempster, D. W. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3051 · Cited by 253
Osteoporosis in Men: A Review of an Underestimated Bone Condition
Rinonapoli, G., Ruggiero, C., Meccariello, L., Bisaccia, M., Ceccarini, P., & Caraffa, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042105 · Cited by 254
Coordinator-based systems for secondary prevention in fragility fracture patients
IOF CSA Fracture Working Group, Marsh, D., Åkesson, K. S., Beaton, D., Bogoch, E. R., Boonen, S., Brandi, M. L., McLellan, A. R., Mitchell, P., Sale, J. E. M., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1642-x · Cited by 248
Self-citationHung, W. W., Egol, K. A., Zuckerman, J. D., & Siu, A. L. (2012) · JAMA · doi:10.1001/jama.2012.4842 · Cited by 248
Falls and Fractures: A systematic approach to screening and prevention
Ambrose, A. F., Cruz, L. C., & Paul, G. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.06.035 · Cited by 247
Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S. E., Reginster, J.-Y., & Cooper, C. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 244
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Update on Osteoporosis Screening and Management
Anam, A. K., & Insogna, K. L. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.016 · Cited by 244
SRT 2104 extends survival of male mice on a standard diet and preserves bone and muscle mass
Mercken, E. M., Mitchell, S. J., Martín‐Montalvo, A., Minor, R. K., Almeida, M., Gomes, A. P., Scheibye‐Knudsen, M., Palacios, H. H., Licata, J. J., Zhang, Y., et al. (2014) · Aging Cell · doi:10.1111/acel.12220 · Cited by 238
Harvey, N. C., McCloskey, E. V., Mitchell, P., Dawson-Hughes, B. F., Pierroz, D. D., Reginster, J., Rizzoli, R., Cooper, C. C., & Kanis, J. A. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3894-y · Cited by 238
Pharmacology of bisphosphonates
Cremers, S., Drake, M. T., Ebetino, F. H., Bilezikian, J. P., & Russell, R. G. G. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13867 · Cited by 232
Bliuc, D., Nguyen, N. D., Nguyen, T. V., & Eisman, J. A. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1968 · Cited by 223
Boonen, S., Adachi, J. D., Man, Z., Cummings, S. R., Lippuner, K., Törring, O., Gallagher, J. C., Farrerons, J., Wang, A., Franchimont, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2784 · Cited by 224
Self-citationVilaca, T., Eastell, R., & Schini, M. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00012-2 · Cited by 221
Secular trends in hip fracture incidence and recurrence
Melton, L. J., Kearns, A. E., Atkinson, E. J., Bolander, M. E., Achenbach, S. J., Huddleston, J. M., Therneau, T. M., & Leibson, C. L. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0742-8 · Cited by 220
Mesenchymal stem cells homing to improve bone healing
Lin, W., Xu, L., Zwingenberger, S., Gibon, E., Goodman, S. B., & Li, G. (2017) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2017.03.002 · Cited by 222
Mortality rates after incident non-traumatic fractures in older men and women
Morin, S. N., Lix, L. M., Azimaee, M., Metge, C. J., Caetano, P. A., & Leslie, W. D. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1480-2 · Cited by 222
Screening for Osteoporosis: An Update for the U.S. Preventive Services Task Force
Nelson, H. D., Haney, E. M., Dana, T., Bougatsos, C., & Chou, R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-2-201007200-00262 · Cited by 214
Evidence‐based guidelines for the management of hip fractures in older persons: an update
Mak, J. C. S., Cameron, I. D., & MARCH, L. M. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03400.x · Cited by 211
Antiresorptive therapies for osteoporosis: a clinical overview
Chen, J. S., & Sambrook, P. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.146 · Cited by 213
Lewiecki, E. M., Dinavahi, R. V., Lazaretti-Castro, M., Ebeling, P. R., Adachi, J. D., Miyauchi, A., Gielen, E., Milmont, C. E., Libanati, C. R., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3622 · Cited by 208
Self-citationTreating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 211
Long-Term Treatment of Postmenopausal Osteoporosis
Brown, J. P. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.301 · Cited by 203
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R. N., Shapiro, C. L., Shields, A. T., Smith, M. R., Srinivas, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0076 · Cited by 199
Eriksen, E. F., Díez‐Pérez, A., & Boonen, S. (2013) · Bone · doi:10.1016/j.bone.2013.09.023 · Cited by 201
Self-citationRoux, C., & Briot, K. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3976-5 · Cited by 197
Fracture mortality: associations with epidemiology and osteoporosis treatment
Sattui, S. E., & Saag, K. G. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.125 · Cited by 199
Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline
Singer, F. R., Bone, H. G., Hosking, D. J., Lyles, K. W., Murad, M. H., Reid, I. R., & Siris, E. S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2910 · Cited by 194
Self-citationHawley, S. J., Javaid, M. K., Prieto‐Alhambra, D., Lippett, J., Sheard, S., Arden, N., Cooper, C. C., & Judge, A. (2016) · Age and Ageing · doi:10.1093/ageing/afv204 · Cited by 192
A Review of Periprosthetic Femoral Fractures Associated With Total Hip Arthroplasty
Marsland, D., & Mears, S. C. (2012) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458512462870 · Cited by 187
Fracture Liaison Service: Impact on Subsequent Nonvertebral Fracture Incidence and Mortality
Huntjens, K. M. B., van Geel, T. A. C. M., van den Bergh, J. P., van Helden, S. H., Willems, P. C. P. H., Winkens, B., Eisman, J. A., Geusens, P., & Brink, P. R. G. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.00223 · Cited by 186
ORWOLL, E. S., Miller, P. D., Adachi, J. D., Brown, J. P., Adler, R. A., Kendler, D. L., Bucci-Rechtweg, C. M., Readie, A., Mesenbrink, P. G., & Weinstein, R. S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.119 · Cited by 185
Self-citationCharacteristics of recurrent fractures
Kanis, J. А., Johansson, H., Odén, A., Harvey, N. C., Gudnason, V. G., Sanders, K. M., Sigurdsson, G. T., Siggeirsdóttir, K., Fitzpatrick, L. A., Borgström, F., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4502-0 · Cited by 185
Rogers, M. J., Mönkkönen, J., & Munoz, M. A. (2020) · Bone · doi:10.1016/j.bone.2020.115493 · Cited by 194
Osteoporosis Medication and Reduced Mortality Risk in Elderly Women and Men
Bliuc, D., Nguyen, N. D., Nguyen, T. V., & Eisman, J. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2730 · Cited by 183
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R. D., Fardellone, P., Féron, J.-M., et al. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.02.014 · Cited by 191
AAOS Clinical Practice Guideline
Roberts, K. C., & Brox, W. T. (2015) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-14-00433 · Cited by 182
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
Osteoporosis, frailty and fracture: implications for case finding and therapy
van den Bergh, J. P., van Geel, T. A., & Geusens, P. P. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.217 · Cited by 179
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 181
Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range
Fuleihan, G. E., Bouillon, R., Clarke, B. L., Chakhtoura, M., Cooper, C. C., McClung, M. R., & Singh, R. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2536 · Cited by 181
Metadata
- Authors
- Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
- Affiliations
- Veterans Health Administration (US)
- University of Maryland, Baltimore (US)
- McMaster University (CA)
- Duke Medical Center (US)
- Hvidovre Hospital (DK)
- Oslo University Hospital (NO)
- Savient Pharmaceuticals (United States) (US)
- Novartis (Switzerland) (CH)
- KU Leuven (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11
- Volume
- 357
- Issue
- 18
- Pages
- 1799-1809
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2324066
- OpenAlex
- W2163830908
- Cited by
- 2,003
- References
- 35
- Citations by year
- 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
- FWCI
- 160.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Savient Pharmaceuticals
- Novo Nordisk
- Servier
- National Institute on Aging (K23AG024787)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
